Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04715126
Other study ID # EB/200401/OXYJUN/AH
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 11, 2021
Est. completion date September 2, 2021

Study information

Verified date October 2021
Source Vedic Lifesciences Pvt. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Terminalia arjuna, commonly known as arjuna, that belongs to the family of Combretaceae. Most clinical and experimental studies for Terminalia arjuna, have suggested that the crude drug possesses anti-ischemic, antioxidant, hypolipidemic, and antiatherogenic activities.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date September 2, 2021
Est. primary completion date September 2, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria: - 1. Participant of either sex, aged = 30 to = 70 years at the time of screening (completed). 2. Participants with normal to high normal blood pressure (BP) [systolic BP = 120 and = 139 mm Hg and/or diastolic BP = 80 and = 89 mm Hg] as defined by "The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)". 3. Participants with normal to mildly deranged 'Left ventricular ejection' as per as per American College of Cardiology: LVEF = 39 and = 55%. 4. BMI = 25 to = 34.9 kg/m2 5. Normal level of Aspartate transaminase (AST) and Alanine transaminase (ALT) as specified by reference range of College of American Pathologists certified laboratory. 6. Normal level of Creatinine as specified by reference range of College of American Pathologists certified laboratory. 7. Participants must have demonstrated their willingness to participate in the study and comply with the study procedures and required visits. 8. Willing to abstain from caffeine, alcohol and related products consumption 12 hours prior to study visits. 9. Those having the ability to understand and sign a written informed consent form, which must be completed prior to study specific requirements being performed. 10. Must be literate and have the ability to complete the study-based questionnaires and requirements. 11. Female participants of childbearing age must be willing to use the accepted methods of contraception during the study. Exclusion Criteria: - Systolic BP =140 mm Hg and/ or Diastolic BP = 90 mm Hg. 2. Fasting blood sugar = 126 mg/dL 3. Presence of any unstable, acutely symptomatic, or life-limiting illness. 4. History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic or neurologic disorders that, in the judgment of the investigator, would interfere with the participant's ability to provide informed consent, comply with the study protocol (that might confound the interpretation of the study results), or put the participant at undue risk. 5. Using Omega fish oil supplements, anticonvulsants, Coenzyme Q10, Vitamin K2, proton pump inhibitors, loop diuretics, anticoagulants, barbiturates, anti-epileptic medications and any herbal supplements (e.g. flax seeds, chia seeds). 6. Chronic use of anti-inflammatory medications (= 5 tablets/20 days in last 3 months). 7. Individuals having a history of smoking or currently smoking and also using any form of smokeless tobacco. 8. High-risk drinking as defined by consumption of 4 or more alcohol containing beverages on any day or 8 or more alcohol containing beverages per week for women and 5 or more alcohol containing beverages on any day or 15 or more alcohol containing beverages per week for men. 9. Binge drinkers as defined by consumption of 4 or more alcohol containing beverages for women and 5 or more alcohol containing beverages for men within 2 hours. 10. Abnormal thyroid stimulating hormone (TSH) levels beyond the defined reference range (<0.4 and > 4.0 IU/ml) 11. Participants unable to walk. 12. Participants with history of chronic caffeine use. 13. Participants who have any other disease or condition, or are using any medication, that in the judgment of the investigator would put him/her at unacceptable risk for participation in the study or may interfere with evaluations in the study or noncompliance with treatment or visits. 14. Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives. 15. Females undergoing hormone replacement treatments. 16. Menopausal females having less than 3 years of menopausal history 17. Those unwilling to abstain from other dietary supplements or medication (e.g. Hepatoprotective agents and other traditional medicines - Ayurveda, Siddhi, Chinese herbal medicine, Naturopathy). 18. Have participated in a study of an investigational product 90 days prior to the screening. 19. Participants with known or suspected hypersensitivity or intolerance to Investigational product. 20. Participants who are unable to comply with study requirements. 21. Any clinical signs or symptoms that in the opinion of investigator, can jeopardize the outcome of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Oxyjun
One capsule to be taken after breakfast with water.
Placebo
One capsule to be taken after breakfast with water.

Locations

Country Name City State
India Dr Rajesh Kewalramani Clinic Mumbai Maharashtra
India Dr. Awate clinic Mumbai Maharashtra
India Dr. Wani's Clinic Mumbai Maharashtra
India Shree Polyclinic, Mumbai Maharashtra

Sponsors (1)

Lead Sponsor Collaborator
Vedic Lifesciences Pvt. Ltd.

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Left ventricle ejection fraction 1. To evaluate the effect of 8-week consumption of Oxyjun on cardiac pumping capacity of study participants as evaluated by Left ventricle ejection fraction (LVEF). Day 0 to Day 56
Secondary Early filling (E) and the atrial phase (A) will be calculated at rest and the E/A ratio Reduction in myocardial stress of study participants as evaluated by decrease in E/A ratio at the end of week 8 (day 56) from baseline as compared to placebo. Day 0 to Day 56
Secondary Myocardial stress Decline in myocardial stress of study participants as assessed by decrease in rate pressure product at the end of week 8 (day 56) from baseline (day 0) as compared to placebo. Day 0 to Day 56
Secondary Fatigue severity scale Reduction in fatigue of study participants as assessed by decrease in Fatigue severity scale at week 4 (day 28), and week 8 (day 56) from baseline (day 0) as compared to placebo. Day 0, Day 28, day 56
See also
  Status Clinical Trial Phase
Completed NCT05986058 - Preliminary Efficacy of a Technology-based Physical Activity Intervention for Older Korean Adults During the COVID-19 Pandemic N/A
Completed NCT01235390 - Effects of the Consumption of California Walnuts on Cardiovascular Health Phase 1
Active, not recruiting NCT04811885 - The Effects of Covid-19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
Recruiting NCT05122689 - Dietary Inorganic Nitrate and the Enteral Microbiome N/A
Completed NCT03119792 - Salud Integral Colombia N/A
Completed NCT01767051 - Children Follow-up of PCOS Women N/A
Recruiting NCT06260579 - Home-based Exercise and Physical Activity Intervention After Kidney Transplantation: Impact of Exercise Intensity N/A
Recruiting NCT05695586 - Effects of the Mindful Self-Compassion (MSC) Program N/A
Withdrawn NCT02202707 - Vasomotor Symptoms and Cardiovascular Control N/A
Active, not recruiting NCT04791618 - MECA Clinical Intervention ( MECA Health360x) N/A
Completed NCT03187704 - Boston Puerto Rican Health Study N/A
Completed NCT02453217 - The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial N/A
Recruiting NCT03090321 - MyHeart Counts Cardiovascular Health Study N/A
Completed NCT01293253 - Effect of Daily Stair Walking on Cardiovascular Health N/A
Active, not recruiting NCT03504059 - School-based Behavioural Intervention to Face Obesity and Promote Cardiovascular Health Among Spanish Adolescents N/A
Completed NCT01551355 - Promoting Heart Health in Preschool Children Phase 3
Completed NCT05004454 - Effect of Bacillus Subtilis BS50 Supplementation on Gastrointestinal Symptoms in Healthy Adults N/A
Recruiting NCT05887622 - The Potassium Supplementation Study N/A
Active, not recruiting NCT04121741 - Singing and Cardiovascular Health in Older Adults N/A
Completed NCT03467061 - The Effect of Dietary Nitrate on the Oral Microbiome N/A